Giuseppina Loglisci

702 total citations
23 papers, 278 citations indexed

About

Giuseppina Loglisci is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Giuseppina Loglisci has authored 23 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Giuseppina Loglisci's work include Acute Myeloid Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Giuseppina Loglisci is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Giuseppina Loglisci collaborates with scholars based in Italy and Switzerland. Giuseppina Loglisci's co-authors include Massimo Breccia, Roberto Latagliata, Adriano Salaroli, Michelina Santopietro, Giuliana Alimena, Laura Cannella, Vincenzo Federico, Alessandra Serrao, Anna Maria Frustaci and Marco Mancini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Giuseppina Loglisci

20 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giuseppina Loglisci Italy 9 191 130 59 56 50 23 278
R. de Paz Spain 8 125 0.7× 40 0.3× 56 0.9× 35 0.6× 35 0.7× 22 270
Pravas Mishra India 12 266 1.4× 179 1.4× 32 0.5× 27 0.5× 37 0.7× 43 379
Douglas Tremblay United States 10 190 1.0× 179 1.4× 41 0.7× 18 0.3× 88 1.8× 20 328
Nahed El Kassar United States 11 135 0.7× 54 0.4× 60 1.0× 19 0.3× 72 1.4× 21 391
Nabil Kabbara France 8 226 1.2× 182 1.4× 91 1.5× 26 0.5× 46 0.9× 14 386
Yasutaka Aoyama Japan 11 138 0.7× 43 0.3× 80 1.4× 46 0.8× 44 0.9× 43 294
Chiara Frairia Italy 10 147 0.8× 90 0.7× 100 1.7× 37 0.7× 86 1.7× 24 296
Vincenzo Mettivier Italy 10 115 0.6× 85 0.7× 57 1.0× 58 1.0× 36 0.7× 13 262
Ryoko Yamasaki Japan 11 166 0.9× 35 0.3× 116 2.0× 67 1.2× 40 0.8× 33 314
Nahoko Hatsumi Japan 10 222 1.2× 59 0.5× 49 0.8× 27 0.5× 60 1.2× 29 297

Countries citing papers authored by Giuseppina Loglisci

Since Specialization
Citations

This map shows the geographic impact of Giuseppina Loglisci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppina Loglisci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppina Loglisci more than expected).

Fields of papers citing papers by Giuseppina Loglisci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppina Loglisci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppina Loglisci. The network helps show where Giuseppina Loglisci may publish in the future.

Co-authorship network of co-authors of Giuseppina Loglisci

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppina Loglisci. A scholar is included among the top collaborators of Giuseppina Loglisci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppina Loglisci. Giuseppina Loglisci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loglisci, Giuseppina, et al.. (2025). JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms. International Journal of Molecular Sciences. 26(21). 10337–10337.
2.
Loglisci, Giuseppina, et al.. (2024). Association of JAK2 Haplotype GGCC_46/1 with the Response to Onco-Drug in MPNs Patients Positive for JAK2V617F Mutation. SHILAP Revista de lepidopterología. 4(3). 241–256.
3.
Breccia, Massimo, Giuseppina Loglisci, Adriano Salaroli, et al.. (2013). Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. Cancer Letters. 333(1). 32–35. 13 indexed citations
4.
5.
Breccia, Massimo, Giuseppina Loglisci, Vincenzo Federico, et al.. (2012). Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Annals of Hematology. 91(9). 1345–1349. 24 indexed citations
6.
Breccia, Massimo, Clara Minotti, Roberto Latagliata, et al.. (2012). Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. Leukemia Research. 37(4). 383–385. 3 indexed citations
7.
Breccia, Massimo, Giuseppina Loglisci, Adriano Salaroli, et al.. (2012). 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leukemia & lymphoma. 53(8). 1558–1560. 11 indexed citations
8.
Breccia, Massimo, Giuseppina Loglisci, Michelina Santopietro, et al.. (2012). Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. Leukemia & lymphoma. 53(12). 2439–2443. 5 indexed citations
9.
Latagliata, Roberto, Alessandro Isidori, Massimo Breccia, et al.. (2012). Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. Acta Haematologica. 129(2). 126–134. 4 indexed citations
10.
Breccia, Massimo, Adriano Salaroli, Giuseppina Loglisci, et al.. (2011). 5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leukemia Research. 35(10). 1409–1411. 2 indexed citations
11.
Girmenia, Corrado, Anna Maria Frustaci, Giuseppe Gentile, et al.. (2011). Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica. 97(4). 560–567. 54 indexed citations
12.
Breccia, Massimo, Corrado Girmenia, Roberto Latagliata, et al.. (2011). LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE. SHILAP Revista de lepidopterología. 3(1). e2011021–e2011021. 14 indexed citations
13.
Latagliata, Roberto, Massimo Breccia, Ida Carmosino, et al.. (2011). Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. Blood. 118(21). 3783–3783. 4 indexed citations
14.
Santini, Valeria, Alessandro Sanna, Alberto Bosi, et al.. (2011). An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy. Blood. 118(21). 1023–1023. 3 indexed citations
15.
Breccia, Massimo, Laura Cannella, Roberto Latagliata, et al.. (2011). Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome. Journal of Clinical Oncology. 29(14). e402–e403. 3 indexed citations
16.
Breccia, Massimo, Vincenzo Federico, Giuseppina Loglisci, et al.. (2011). MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. Blood. 118(21). 3793–3793. 1 indexed citations
17.
Breccia, Massimo, Vincenzo Federico, Roberto Latagliata, et al.. (2010). Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leukemia Research. 35(2). 159–162. 26 indexed citations
18.
Breccia, Massimo, Giuseppina Loglisci, Adriano Salaroli, et al.. (2010). Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response. Acta Haematologica. 124(1). 46–48. 18 indexed citations
19.
Latagliata, Roberto, Massimo Breccia, Ida Carmosino, et al.. (2010). “Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leukemia Research. 34(11). 1472–1475. 35 indexed citations
20.
Breccia, Massimo, Roberto Latagliata, Laura Cannella, et al.. (2010). Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leukemia & lymphoma. 51(5). 783–788. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. de Paz Breakdown of academic impact, for papers by Pravas Mishra Breakdown of academic impact, for papers by Douglas Tremblay Breakdown of academic impact, for papers by Nahed El Kassar Breakdown of academic impact, for papers by Nabil Kabbara Breakdown of academic impact, for papers by Yasutaka Aoyama Breakdown of academic impact, for papers by Chiara Frairia Breakdown of academic impact, for papers by Vincenzo Mettivier Breakdown of academic impact, for papers by Ryoko Yamasaki Breakdown of academic impact, for papers by Nahoko Hatsumi
Rankless by CCL
2026